Caisse de Depot Et Placement Du Quebec Adds $75M in Gilead Sciences, Inc. ($GILD)
The fund boosted its holdings in Gilead Sciences by 62.6%, adding 594,774 shares.
Key Points
- Caisse de Depot Et Placement Du Quebec increased its stake in Gilead Sciences, Inc. by 62.6%, adding 594,774 shares to total 1,544,223 shares valued at $191.2 million.
- Gilead Sciences, Inc. has a market cap of about $153.8 billion and a forward P/E ratio of 12.8, trading near $123.84.
- Analysts like Cantor Fitzgerald and Maxim Group have reiterated or upgraded their ratings, with targets as high as $180.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Caisse de Depot Et Placement Du Quebec significantly increased its holdings in Gilead Sciences, Inc. (NasdaqGS: GILD) by 62.6% as of its latest SEC filing. The fund added 594,774 shares, bringing its total to 1,544,223 shares, valued at approximately $191.2 million.
Caisse de Depot Et Placement Du Quebec vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Caisse de Depot Et Placement Du Quebec's Gilead Sciences Position
Caisse de Depot Et Placement Du Quebec boosted its position in Gilead Sciences by 62.6%, increasing its shares from 949,449 to 1,544,223. This substantial addition reflects the fund's growing confidence in Gilead, with the total value of the position now standing at about $191.2 million.
Other Institutional Activity in Gilead Sciences
Among other institutional investors, BlackRock, Inc. reduced its holdings by 4.18 million shares, ending with 119 million shares valued at $16.59 billion, a 3.4% decrease. Vanguard Capital Management LLC opened a new position with 80.65 million shares worth $11.24 billion. FMR LLC increased its stake by 6.33 million shares, bringing its total to 71.91 million shares valued at $10.02 billion, marking a 9.6% increase. State Street Corp slightly trimmed its holdings by 381,933 shares, maintaining 59.86 million shares valued at $8.34 billion, a 0.6% decrease.
Gilead Sciences, Inc. Stock Down 13.3%
Shares of Gilead Sciences, Inc. traded near $123.84 on Friday. The company has a market cap of approximately $153.8 billion. It boasts a P/E ratio of 16.8 and a forward P/E of 12.8, with a relatively low beta of 0.331, indicating less volatility than the market. The stock's 52-week range spans from $106.84 to $157.29, with a 50-day moving average of $130.55 and a 200-day moving average of $129.61. Gilead maintains a current ratio of 1.97 and a quick ratio of 1.54, with a debt-to-equity ratio of 94.64.
$GILD stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
In its most recent earnings report, Gilead Sciences posted revenue of $29.74 billion, reflecting a 4.4% growth. The company achieved a net margin of 30.99% and a return on equity of 43.36%. Earnings per share stood at $7.36. The next earnings release is scheduled for August 6, 2026.
Dividend
Gilead Sciences offers an annual dividend rate of $3.28, yielding 2.65%. The company's dividend payout ratio is 43.4%.
Insider Buying and Selling at Gilead Sciences, Inc.
Recent insider activity at Gilead Sciences includes planned sales by CFO Andrew Dickinson and Chief Comm & Corp Aff Officer Johanna Mercier, each selling 3,000 shares on June 15, 2026. On June 10, 2026, Dickinson also bought 2,796 shares, while CEO Daniel Patrick O'Day sold 8,779 shares.
Analysts Set New Price Targets
On June 16, 2026, Cantor Fitzgerald reiterated its buy rating on Gilead Sciences with a $155 price target. Maxim Group upgraded the stock to a buy with a $165 target on May 20, 2026. The consensus among 28 analysts is a buy, with an average target price of $157.57.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company based in Foster City, California. It focuses on discovering and developing medicines for unmet medical needs, particularly in HIV, hepatitis, and oncology. The company employs around 17,000 people and is led by CEO Daniel Patrick O'Day.
Bottom Line
This substantial increase by Caisse de Depot Et Placement Du Quebec in Gilead Sciences, Inc. highlights the fund's confidence in the healthcare giant. Investors often track such moves for insights into institutional sentiment. Remember, 13F filings are backward-looking and may not reflect current positions.
Get Gilead Sciences, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GILD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.